Public-Private Collaborations in Drug Development: Boosting Innovation or Alleviating Risk?
| Autor: | Thomas Crispeels, Ilse Scheerlinck, Jurgen Willems |
|---|---|
| Přispěvatelé: | Business technology and Operations, Faculty of Economic and Social Sciences and Solvay Business School, Vesalius College |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
211903 Betriebswissenschaften
509018 Knowledge management Trial success Public–private collaboration Arzneistoffanalyse Management Information Systems 509018 Wissensmanagement 505027 Administrative studies 211903 Science of management Management of Technology and Innovation 0502 economics and business 050602 political science & public administration Popular belief 605005 Publikumsforschung Boosting (doping) business.industry 301201 Arzneimittel 05 social sciences 502024 Public economy cross-sector collaboration Public relations 502024 Öffentliche Wirtschaft drug development 0506 political science Test (assessment) 605005 Audience research Drug development 505027 Verwaltungslehre 301201 Pharmaceutical and drug analysis Business 050203 business & management |
| DOI: | 10.1080/14719037.2017.1302247 |
| Popis: | Consistent with popular belief among certain academics, practitioners, and policy makers, we hypothesize that collaboration between private and public organizations promotes success. We test this hypothesis for data on clinical trial success. Contrary to this popular belief, our results do not support the beneficial effect of within- and cross-sector collaborations. In contrast, we find that trials from single private companies are four times more likely to be successful than are trials in which public and private organizations collaborate. Hence, our results indicate that companies engage with public partners to mitigate development risks, not to exchange knowledge or technologies with them. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|